Clinical Trial Update: Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating toripalimab with concurrent chemoradiotherapy in unresectable locally recurrent nasopharyngeal carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Toripalimab (Toripalimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Carcinoma, Chemotherapy | Phase 3 | Status: RECRUITING